Effect of ribociclib Plus fulvestrant on overall survival in the treatment of advanced breast cancer - updated MONALEESA-3 results

被引：0

作者：

Dubianski, Roman ^{[1
]}

机构：

[1] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Breast Canc & Reconstruct Surg, WK Roentgena 5 St, PL-02781 Warsaw, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2022年 / 18卷 / 03期

关键词：

breast cancer; ribociclib; fulvestrant; CDK4/6; inhibitor; PHASE-I; TRIAL; THERAPY;

D O I：

10.5603/OCP.2021.0034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The results of the treatment of ER-positive/HER2-negative advanced breast cancer have been improved in the last few years due to the use of CDK4/6 inhibitors combined with endocrine therapy. Ribociclib with fulvestrant significantly prolonged progression-free survival and overall survival in the phase-III MONALEESA-3 trial. The newest update of the trial (after 56.3 months of observation) showed significant improvement in overall survival in the experimental arm for more than ayear: mOS was 53.7 months in the ribociclib plus fulvestrant arm and 41.5 months in the placebo plus fulvestrant arm (risk reduction of 27%). Subgroup analysis confirmed the efficacy of the treatment in both the first and second lines of treatment. The study also showed that adding ribociclib to the endocrine treatment prolongs the median time to chemotherapy. No new toxicities were observed in longer observation.

引用

页码：189 / 194

页数：6

共 50 条

[41] Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial
Lu, Y-S.
Bardia, A.
Vazquez, R. V.
Colleoni, M. A.
Wheatley-Price, P.
Im, Y-H.
Babu, G.
Tripathy, D.
Lanoue, B. R.
Chandiwana, D.
Ridolfi, A.
Hughes, G.
Zarate, J. P.
Gounaris, I.
Harbeck, N.
ANNALS OF ONCOLOGY, 2019, 30
[42] On-treatment (tx) dynamic circulating tumor DNA changes (ΔctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER22 advanced breast cancer (ABC) in MONALEESA-3 (ML-3)
Chia, Stephen K. L.
Solovieff, Nadia
Joshi, Mukta
Im, Seock-Ah
Bianchi, Giulia Valeria
de la Cruz-Merino, Luis
Jerusalem, Guy Heinrich Maria
Sonke, Gabe S.
Nusch, Arnd
Beck, J. Thaddeus
Slamon, Dennis J.
Wang, Craig
Zarate, Juan Pablo
Su, Fei
Neven, Patrick
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Tripathy, Debu
Im, Seock-Ah
Colleoni, Marco
Franke, Fabio
Bardia, Aditya
Harbeck, Nadia
Hurvitz, Sara A.
Chow, Louis
Sohn, Joohyuk
Lee, Keun Seok
Campos-Gomez, Saul
Vazquez, Rafael Villanueva
Jung, Kyung Hae
Babu, K. Govind
Wheatley-Price, Paul
De laurentiis, Michelino
Im, Young-Hyuck
Kuemmel, Sherko
El-Saghir, Nagi
Liu, Mei-Ching
Carlson, Gary
Hughes, Gareth
Diaz-Padilla, Ivan
Germa, Caroline
Hirawat, Samit
Lu, Yen-Shen
LANCET ONCOLOGY, 2018, 19 (07): : 904 - 915
[44] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, C. S.
Paluch-Shimon, S.
Campone, M.
Petrakova, K.
Blackwell, K. L.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D. A.
Mondal, S.
Su, F.
Miller, M.
Elmeliegy, M.
Germa, C.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
[45] Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2-Advanced Breast Cancer
不详
ONCOLOGIST, 2021, 26 : S5 - S6
[46] Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2,-3, and-7 trials
Beck, J. T.
Neven, P.
Sohn, J.
Chan, A.
Sonke, G. S.
Bachelot, T.
Campos-Gomez, S.
Martin, M.
Bardia, A.
Alam, J.
Miller, M.
Diaz-Padilla, I.
Kong, O.
Hart, L.
CANCER RESEARCH, 2019, 79 (04)
[47] Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Campone, Mario
Im, Seock-Ah
Iwata, Hiroji
Clemons, Mark
Ito, Yoshinori
Awada, Ahmad
Chia, Stephen
Jagiello-Gruszfeld, Agnieszka
Pistilli, Barbara
Tseng, Ling-Ming
Hurvitz, Sara
Masuda, Norikazu
Cortes, Javier
De Laurentiis, Michele
Arteaga, Carlos L.
Jiang, Zefei
Jonat, Walter
Le Mouhaer, Sylvie
Sankaran, Banu
Bourdeau, Laurence
El-Hashimy, Mona
Sellami, Dalila
Baselga, Jose
EUROPEAN JOURNAL OF CANCER, 2018, 103 : 147 - 154
[48] Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA(ML)-2.
Hart, Lowell L.
Bardia, Aditya
Beck, Joseph Thaddeus
Chan, Arlene
Neven, Patrick
Hamilton, Erika P.
Sohn, Joohyuk
Sonke, Gabe S.
Bachelot, Thomas
Spring, Laura
Le Gac, Fabienne
Hu, Huilin
Gao, Ming
De laurentiis, Michelino
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
Huang, C-S.
Toi, M.
Im, Y-H.
Iwata, H.
Sohn, J.
Wang, H-C.
Masuda, N.
Im, S-A.
Lu, Y.
Haddad, N.
Sakaguchi, S.
Hurt, K.
Neven, P.
Llombart-Cussac, A.
Sledge, G.
ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1259
[50] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
Toi, Masakazu
Huang, Chiun-Sheng
Im, Young-Hyuck
Sohn, Joohyuk
Zhang, Wei
Sakaguchi, Sachi
Haddad, Nadine
van Hal, Gertjan
Sledge Jr, George W.
CANCER SCIENCE, 2023, 114 (01) : 221 - 226

← 1 2 3 4 5 →